Ovid Therapeutics (OVID) Accounts Payables (2016 - 2026)

Ovid Therapeutics has reported Accounts Payables for 11 years, with the latest figure at $8.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 355.18% year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (up 355.18% YoY), and the FY2025 full-year result was $2.0 million, down 38.72% from the prior year.
• Accounts Payables for Q1 2026 stood at $8.9 million, up from $2.0 million in the prior quarter.
• The five-year high for Accounts Payables was $8.9 million in Q1 2026, with the low at $1.0 million in Q3 2022.
• Historically, Accounts Payables has averaged $3.1 million across 5 years, with a median of $2.7 million in 2024.
• The largest YoY upside for Accounts Payables was 407.58% in 2022 against a maximum downside of 72.6% in 2022.
• Ovid Therapeutics' Accounts Payables stood at $2.0 million in 2022, then surged by 89.61% to $3.7 million in 2023, then fell by 13.8% to $3.2 million in 2024, then sank by 38.72% to $2.0 million in 2025, then soared by 353.78% to $8.9 million in 2026.
• The last three Accounts Payables figures came in at $8.9 million (Q1 2026), $2.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.